Home / Uncategorized / New melanoma drug doubles survival time, study shows

New melanoma drug doubles survival time, study shows

Patients with metastatic melanoma typically live six to ten months; Zelboraf prolonged life expectancy to 16 months

Read the rest here:
New melanoma drug doubles survival time, study shows

If you enjoyed this post, make sure you subscribe to my RSS feed!

About Philippe Matthews

Scroll To Top